Hanyu Medical

Shanghai-based Hanyu Medical Technology Co., Ltd. is a medical device company established in 2016, focused on the research, development, and commercialization of innovative medical devices for structural heart disease. The company was founded by Dai Yufeng, who serves as CEO and has a diverse background as an orthopedic surgeon, in medical device sales, and in secondary market investment. This varied experience in medicine, management, and capital operations underpins the company's strategy.

Hanyu Medical's core business revolves around providing less invasive treatment options for heart valve diseases, primarily targeting the transcatheter mitral valve (TMV) market in China. Its flagship product is the ValveClamp, a transcatheter mitral valve repair (TMVr) system designed for the minimally invasive treatment of mitral regurgitation (MR), a condition where the heart's mitral valve doesn't close properly. The original design patent for ValveClamp originated from the team of Academician Ge Junbo of Zhongshan Hospital, which Hanyu Medical acquired and developed for commercialization. In September 2023, the ValveClamp was officially approved by China's National Medical Products Administration, becoming the first domestically developed MR interventional device on the market. The system is designed to be easier to operate than some international counterparts, with a shorter surgical path and the ability to be used with ultrasound guidance, potentially reducing patient exposure to radiation.

The company's business model is centered on the production and sale of these specialized medical devices to hospitals and clinics. Having completed confirmatory clinical trials in March 2021, the ValveClamp was anticipated to enter hospitals for clinical use in early 2024. Hanyu Medical's revenue stream, previously reliant on pet medical services, is expected to scale significantly with the commercialization of ValveClamp and subsequent products. The firm has raised substantial capital through multiple funding rounds to support its extensive R&D and commercialization efforts, with investors including Yunfeng Capital, CITIC, and Highlight Capital. While the company has pursued listings on both the Hong Kong Stock Exchange and the STAR Market, these IPO attempts were withdrawn due to market conditions.

Beyond its primary focus on human healthcare, Hanyu Medical has diversified into the veterinary market through its holding subsidiary, Yuanyu Medical. This subsidiary has developed V-Clamp, a miniaturized version of ValveClamp for treating MR in pet dogs, and is noted as the first company globally to commercialize such a device. The company's product pipeline is robust, featuring additional transcatheter heart repair products, transcatheter valve replacement products, and electrophysiology products aimed at providing comprehensive solutions for structural heart disease. Keywords: Hanyu Medical, structural heart disease, medical devices, transcatheter mitral valve repair, TMVr, ValveClamp, mitral regurgitation, minimally invasive surgery, cardiac intervention, Ge Junbo, Dai Yufeng, China NMPA, veterinary cardiology, V-Clamp, heart valve disease, medical technology, cardiovascular devices, interventional cardiology, Yunfeng Capital, CITIC